This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Asthma
  • /
  • Benralizumab for the treatment of asthma.

Benralizumab for the treatment of asthma.

Read time: 1 mins
Published:1st Dec 2017
Author: Matera MG, Rogliani P, Calzetta L, Canonica GW, Cazzola M.
Source: Drugs of Today
Availability: Pay for access, or by subscription
Ref.:Drugs Today (Barc). 2017;53(12):633-645.

Benralizumab is a humanized monoclonal antibody directed at the a subunit of the interleukin-5 receptor (IL-5R) that is under clinical development. The binding of benralizumab with the alpha chain of IL-5R results in inhibition of hetero-oligomerization of alpha and beta subunits and thus no signal transduction occurs. Consequently, this inhibition prevents proliferation of eosinophils and basophils and the cascade of events following it. Several pivotal trials have documented that benralizumab reduces asthma exacerbation rates with a significant increase in time to the next exacerbation, statistically improves prebronchodilator forced expiratory volume in 1 second (FEV1) and disease-specific health-related quality of life, and is well tolerated in patients with severe asthma and blood eosinophil counts greater than or equal to 150 cells/mcL.


Read abstract on library site

Access full article